» Articles » PMID: 24001454

Increased Expression of Slug and Vimentin As Novel Predictive Biomarkers for Lymph Node Metastasis and Poor Prognosis in Colorectal Cancer

Overview
Journal Carcinogenesis
Specialty Oncology
Date 2013 Sep 5
PMID 24001454
Citations 69
Authors
Affiliations
Soon will be listed here.
Abstract

Slug and Vimentin genes play a critical role in regulating epithelial-mesenchymal transition (EMT) via downregulation of epithelial markers and upregulation of mesenchymal markers. The present study evaluated the clinical significance of Slug and Vimentin expression as potential disease biomarkers in colorectal cancer (CRC). At first, the biological role of Slug in CRC was assessed by RNA interference in CRC cell lines to assess tumor progression, invasion and migration. Next, we analyzed Slug and Vimentin expression in surgical tissue specimens from 181 CRC patients (Cohort 1) by quantitative real-time reverse transcription-PCR and 208 patients (Cohort 2) by immunohistochemistry. Knockdown of Slug using small interfering RNA in CRC cell lines resulted in inhibition of EMT, reduced cell proliferation, invasion and migration in CRC cells. Interestingly, Slug and Vimentin expression in cancer tissues was significantly higher in patients with higher T stage, lymph node involvement, liver metastasis and advanced tumor node metastasis stages. A significant correlation was observed between Slug and Vimentin expression in CRC (messenger RNA: ρ = 0.546, protein: ρ = 0.405), and increased expression of Slug and Vimentin was significantly associated with poor prognosis. Furthermore, increased expression of Slug emerged as an independent prognostic factor and a predictive marker of lymph node metastasis in CRC patients. Our data provide novel evidence for the biological and clinical significance of Slug and Vimentin expression as potential predictive biomarkers for identifying patients with lymph node metastasis or poor prognosis in CRC.

Citing Articles

Simultaneous effect of miR-21 suppression and miR-143 restoration on inhibition of proliferation and migration in SW-480 colorectal cancer cells.

Tohidast M, Amini M, Doustvandi M, Hosseini S, Bilan F, Mozammel N Bioimpacts. 2025; 15:30255.

PMID: 39963562 PMC: 11830141. DOI: 10.34172/bi.30255.


Pathogenetic development, diagnosis and clinical therapeutic approaches for liver metastasis from colorectal cancer (Review).

Jin Z, Li Y, Yi H, Wang M, Wang C, Du S Int J Oncol. 2025; 66(3).

PMID: 39950314 PMC: 11844340. DOI: 10.3892/ijo.2025.5728.


Morphological and functional analysis of colorectal cancer cell lines in 2D and 3D culture models.

Shinji S, Ogawa Y, Yamada T, Matsuda A, Uehara K, Yokoyama Y Sci Rep. 2025; 15(1):3047.

PMID: 39856264 PMC: 11760527. DOI: 10.1038/s41598-025-87660-x.


overexpression inhibits colorectal cancer cell migration through the regulation of epithelial‑mesenchymal transition.

Wanna-Udom S, Aluksanasuwan S, Somsuan K, Mongkolwat W, Sakulsak N Mol Med Rep. 2024; 30(5).

PMID: 39301629 PMC: 11406482. DOI: 10.3892/mmr.2024.13325.


Markers of Epithelial-Mesenchymal Transition and Mucinous Histology Are Significant Predictors of Disease Severity and Tumor Characteristics in Early-Onset Colorectal Cancer.

Djikic Rom A, Dragicevic S, Jankovic R, Radojevic Skodric S, Sabljak P, Markovic V Diagnostics (Basel). 2024; 14(14).

PMID: 39061649 PMC: 11275501. DOI: 10.3390/diagnostics14141512.